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Abstract
Background: RASSF1A gene silencing by DNA methylation has been suggested as a major event in pancreatic
endocrine tumor (PET) but RASSF1A expression has never been studied. The RASSF1 locus contains two CpG islands
(A and C) and generates seven transcripts (RASSF1A-RASSF1G) by differential promoter usage and alternative
splicing.
Methods: We studied 20 primary PETs, their matched normal pancreas and three PET cell lines for the (i)
methylation status of the RASSF1 CpG islands using methylation-specific PCR and pyrosequencing and (ii)
expression of RASSF1 isoforms by quantitative RT-PCR in 13 cases. CpG island A methylation was evaluated by
methylation-specific PCR (MSP) and by quantitative methylation-specific PCR (qMSP); pyrosequencing was applied
to quantify the methylation of 51 CpGs also encompassing those explored by MSP and qMSP approaches.
Results: MSP detected methylation in 16/20 (80%) PETs and 13/20 (65%) normal pancreas. At qMSP, 11/20 PETs
(55%) and 9/20 (45%) normals were methylated in at least 20% of RASSF1A alleles.
Pyrosequencing showed variable distribution and levels of methylation within and among samples, with PETs
having average methylation higher than normals in 15/20 (75%) cases (P = 0.01). The evaluation of mRNA
expression of RASSF1 variants showed that: i) RASSF1A was always expressed in PET and normal tissues, but it was,
on average, expressed 6.8 times less in PET (P = 0.003); ii) RASSF1A methylation inversely correlated with its
expression; iii) RASSF1 isoforms were rarely found, except for RASSF1B that was always expressed and RASSF1C
whose expression was 11.4 times higher in PET than in normal tissue (P = 0.001). A correlation between RASSF1A
expression and gene methylation was found in two of the three PET cell lines, which also showed a significant
increase in RASSF1A expression upon demethylating treatment.
Conclusions: RASSF1A gene methylation in PET is higher than normal pancreas in no more than 75% of cases and
as such it cannot be considered a marker for this neoplasm. RASSF1A is always expressed in PET and normal
pancreas and its levels are inversely correlated with gene methylation. Isoform RASSF1C is overexpressed in PET
and the recent demonstration of its involvement in the regulation of the Wnt pathway points to a potential
pathogenetic role in tumor development.
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Background
Pancreatic endocrine tumors (PET) are rare neoplasms
whose molecular pathogenesis is largely unknown. Silen-
cing of the RASSF1A gene by methylation has been pro-
posed as a crucial pathogenetic event in PET by five
studies, all of which used the very same methylation-
specific PCR (MSP) assay to interrogate the same region
of the gene [1-5]. Two of these five papers assessed the
methylation status of several candidate tumor suppres-
sor genes and reported the methylation of RASSF1A in
75% [3] and 83% [2] of PET. This high rate of RASSF1A
methylation in PETs was confirmed in the other three
studies, where the rate reported ranged from 60% to
100% of cases [1,4,5]. However, the formal proof that
the RASSF1A gene silencing by methylation in PET is
associated with loss of its expression has never been
reported.
In tumor types other than PET, RASSF1A involvement
was assessed by a quantitative MSP assay (qMSP), ana-
lyzing a region of RASSF1A different from the one
investigated by MSP in PET [6-10]. For some of these
tumors methylation was associated with down-regula-
tion of the gene expression [11-19].
Ras Association Domain Family 1 (RASSF1) is a puta-
tive tumor suppressor gene localized at chromosome
3p21.3 that has been reported to inhibit tumor growth
in in vitro and in vivo systems [20-23]. RASSF1 locus
generates seven different transcript variants (RASSF1A-
G) by differential promoter usage and alternative spli-
cing [24]. RASSF1A has been considered a player of
inhibitory functions of Ras on cell growth by acting as
downstream agent and as such its inactivation is
believed to result in the indirect activation of the Ras
pathway. Other studies however have also assigned com-
plex roles in cell functions to this gene [25,26].
Two CpG islands are associated with RASSF1 regula-
tory region: CpG island A extending in the regulatory
region common to RASSF1A, D, E, F and G; CpG island
C in the regulatory region of RASSF1C. Little is known
about the influence of CpG islands on RASSF1B. The
main RASSF1 variants that are ubiquitously expressed in
normal tissues are RASSF1A and RASSF1C [24]. No
information is available regarding the expression of
RASSF1 isoforms in PET.
In this study, we evaluated the putative role of
RASSF1A methylation as a possible tumor specific and
transcription regulatory event occurring in PET. To this
end, we applied both the MSP and qMSP approaches
indicated above in a set of 20 PETs and matched normal
pancreas together with the evaluation of RASSF1 gene
expression in 13 cases. We also assessed the methylation
status of each of the CpG sites encompassing a large
area of the regulatory region, including the CpGs
interrogated by MSP and qMSP assays, with methyla-
tion-sensitive pyrosequencing. This technique allows
relative quantification of methylated CpGs in relation to
unmethylated CpGs for each of the CpG sites tested.
Methods
Samples and nucleic acids extraction
Twenty primary sporadic PET (Table 1) with matched
normal pancreas were studied. Samples were obtained
in accordance with the Verona University and Hospital
Trust Ethics Committee and PET were classified accord-
ing to WHO criteria [27]. Normal pancreas was taken
far away (at least 2 cm) from the neoplastic lesion and
was macroscopically and histologically normal at patho-
logical evaluation. All PET samples were negative for
MEN1 gene mutation (data not shown) and there was
no family history for MEN1, VHL or any other familial
cancer predisposing syndrome.
Nucleic acids were prepared from 12 cryostatic sec-
tions, with tumor cellularity checked every four sections.
Tumor cellularity was always over 90%. DNA was puri-
fied by QiAamp DNA Mini Kit (Qiagen), following
manufacturer’s instructions. RNA was extracted with
TRIzol Reagent (Invitrogen) following the manufacturer
instructions, then treated with DNAse I (Invitrogen) for
15 minutes at room temperature, and finally incubated
at 65°C for 10 minutes for enzyme inactivation. As a
control of the DNAse I efficiency, a DNA sample was
Table 1 Clinical data of PET cases
Case Sex Age (years) Tumor type WHO classification*
1 M 53 non-functioning WDEC
2 M 42 non-functioning WDEC
3 M 51 insulinoma WDET
4 M 44 non-functioning WDEC
5 M 48 non-functioning WDEC
6 M 51 insulinoma WDET
7 F 66 non-functioning WDET
8 F 65 non-functioning WDET
9 M 35 non-functioning WDEC
10 F 70 non-functioning WDEC
11 M 76 non-functioning WDEC
12 F 40 non-functioning WDEC
13 M 41 insulinoma WDET
14 M 40 non-functioning WDEC
15 M 68 non-functioning WDEC
16 F 47 non-functioning WDET
17 M 48 non-functioning WDET
18 M 41 gastrinoma WDEC
19 M 70 non-functioning WDEC
20 F 46 gastrinoma WDET
* WDEC: well-differentiated endocrine carcinoma; WDET: well-differentiated
endocrine tumor.
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subjected to DNAse I treatment at the same conditions
and loaded on agarose gel.
Cell lines and demethylating treatment
PET cell lines CM, QGP1 and BON were grown in cul-
ture medium containing RPMI 1640 supplemented with
2 mM glutamine and 10% FBS and incubated at stan-
dard conditions (37°C with 5% CO2). Cell lines were
treated with the enzymatic inhibitor 5’-aza-2’-deoxycyti-
dine (DAC) (Sigma-Aldrich), previously solubilized in
DMSO and stored at -80°C until use. Cells treated with
the inhibitor were grown in presence of 2.5 μM DAC
for 6 days.
Optimization of bisulfite treatment of DNA
DNA was chemically modified with sodium bisulfite
using MethylSeq Kit (Applied Biosystems) to convert
unmethylated cytosine to uracil, while methylated cyto-
sines resist conversion. Duration of bisulfite treatment
necessary to determine complete cytosines modification
was assessed by incubating DNA with sodium bisulfite
for 4, 8 and 16 hours at 50°C in a heat-block. Complete
conversion of cytosines occurred after 16 hours treat-
ment and the DNA obtained was used for subsequent
experimental procedures.
RASSF1A methylation-specific PCR (MSP)
Methylation-specific PCR (MSP) was performed accord-
ing to Pizzi et al. [5]. Reference unmethylated DNA was
from healthy donor peripheral blood mononuclear cells.
Reference full methylated DNA was CpGenome Univer-
sal Methylated DNA (Chemicon International).
Quantitative methylation-specific PCR
Quantitative MSP (qMSP) was performed as described
[6,8] with minor modifications reported in Additional
file 1. Primers are listed in Additional file 2, Table S1.
The methylation level of RASSF1A was calculated as the
ratio of methylated RASSF1A to MYOD1, the latter
representing the total input unmethylated DNA [28]. To
classify samples as methylated, we applied the same cut-
off used by Xing et al. [10]. The 20% cut-off point at
qMSP analysis was chosen with a conservative assump-
tion that all of the cells in a sample were tumor cells
without normal cell contamination and without loss of
heterozygosity in the RASSF1A locus. Thus, a cut-off
point of 20% of total alleles for RASSF1A methylation
implies that 20% of all of the tumor cells carry RASSF1A
methylation, if both alleles are methylated in one cell. In
reality, the tumor tissue is not 100% pure, and there
may be also loss of heterozygosity in the RASSF1A
locus. Therefore the 20% cut-off point of total alleles for
RASSF1A methylation actually reflects the presence of a
clone of more than 20% of the total number of tumor
cells [10].
Pyrosequencing of bisulfite-modified DNA
Bisulfite-modified DNAs were evaluated by pyrosequen-
cing [29] as recommended (Biotage AB), using primers
and conditions as reported in Additional file 1 and in
Additional file 2, Table S1. The degree of methylation at
each CpG position was determined from the ratio of C
and T by the Pyro Q-CpG Software (Biotage AB). Pyro-
sequencing was performed on the sense and antisense
strand of RASSF1A (nucleotides -163 to +262 in chro-
mosome 3: 50353109-50353534, NC_0000003.10) and of
RASSF1C (nucleotides -86 to +193 in chromosome 3:
50349706-50349985, NC_0000003.10).
Identification of alternatively spliced mRNA isoforms of
RASSF1 transcribed from CpG island A
Isoforms A, D, E, F and G originate from alternative
splicing of RASSF1A gene. Taking advantage of their dif-
ferent length, isoforms A, D, E and F were identified by
microfluidic chip-electrophoretic separation (DNA 1000
chip, 2100 Bioanalyzer, Agilent Technologies) of PCR
products. The PCR amplification of cDNAs used pri-
mers designed in the first and last exon of the gene
(NCBI Reference Sequence NM_007182). As RASSF1G
lacks the last exon of RASSF1A, it was amplified sepa-
rately with opportune primers. The PCR primers used
are listed in Additional file 2, Table S1.
Measurement of mRNA expression by quantitative
reverse transcription-polymerase chain reaction (qRT-PCR)
RNA samples were retrotranscribed to cDNA using
the First Strand cDNA Synthesis Kit (Roche). A
reverse transcriptase minus cDNA was prepared for
each sample as a control. qRT-PCR conditions and
primers are reported in Additional file 1 and in Addi-
tional file 2, Table S1. The relative expression level
was calculated using transcript level of RPLPO as
reference gene and the standard (= 1) was the average
of the levels of expression of all samples. qRT-PCR
data analysis was performed according to the com-
parative method following the User Bulletin #2
(Applied Biosystems).
Statistical analysis
Pearson’s correlation (r) and Student’s t-test were used
to compare mRNA expression and differentially methy-
lated regions between groups of samples. Pairwise t-test
or Spearman Rank (rho) correlation was used to com-
pare expression in matched PET and normal samples. P
values less than 0.05 were considered statistically
significant.
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Results
The methylation status of CpG islands A and C of the
RASSF1 locus (Figure 1) was assessed in a series of 20
PET and matched normal tissues (Table 1). Methyla-
tion of CpG island A was first evaluated by the qualita-
tive methylation-specific PCR (MSP) used in papers
dealing with PET [1-5] and then by a quantitative
methylation - specific PCR (qMSP) applied in the
study of other tumor types [6-10]. The regions of CpG
island A analyzed by MSP and qMSP were further
investigated by pyrosequencing, which provided the
methylation status of 51 CpGs of the island A that
also encompasses those explored by MSP and qMSP
approaches. Analysis of the expression of the diverse
RASSF1 isoforms completed the study. The analysis of
CpG island C was performed by pyrosequencing analy-
sis of 37 individual CpGs.
Methylation-specific PCR showed a high frequency of
RASSF1A methylation in PET and normal pancreas
MSP detected methylation in 16 of 20 (80%) PETs and
13 of 20 (65%) normal pancreas (Additional file 3, Fig-
ure S1A). In particular, methylation was detected in 12
PETs and matched normals, was absent in both PET
and matched normal in 3 cases, while in five cases it
was discordantly present in either PET (4 cases) or nor-
mal (1 case).
Quantitative methylation-specific PCR showed variable
RASSF1A methylation among PET and normal pancreas
All PET and normal samples showed variable levels of
methylation at qMSP, but only 11/20 PETs (55%) and 9/
20 (45%) normals had a methylation level in at least
20% of the RASSF1A alleles (Additional file 3, Figure
S1B). The cut-off point of 20% of total alleles for
RASSF1A methylation implies that 20% of cells in a
sample carry RASSF1A methylation [10].
Using this cut-off, methylation in paired PET/normal
cases was as follows: 6 both methylated, 6 both
unmethylated, 5 methylated in PET, 3 methylated in
normal. The qMSP methylation levels in PET and
matched normals showed a higher degree of methylation
in neoplastic tissues with respect to normals in 8 cases
and a lower degree in 9 cases; the remaining 3 cases
had similar methylation levels in PET and normal.
Pyrosequencing revealed that RASSF1A promoter and
first exon are variably methylated within and among PETs
and normal pancreas
Pyrosequencing was applied to determine the methyla-
tion level of 51 CpGs within CpG island A of
RASSF1A, including 17 CpGs in the promoter and 34
CpGs in the first exon. In fact, this technique is able
to provide the level of methylation of single CpGs (Fig-
ure 2). RASSF1A methylation showed a high variability
in terms of distribution and level among PET and nor-
mal samples (Figure 3). Analysis of the RASSF1A anti-
sense DNA strand confirmed the results obtained for
the sense strand.
Table 2 lists the average methylation levels of promo-
ter, first exon and of the CpG island A of RASSF1A in
20 tumors and their matched normal samples. By con-
sidering the average methylation of all 51 CpGs, methy-
lation was higher in tumor than in normal tissue in 15/
20 (75%) cases (pairwise t-test, P = 0.01) (Figure 3,
Table 2); of the remaining 5 cases, 2 cases had similar
methylation level in normal and tumor (cases 1 and 9),
while 3 cases had normal showing higher methylation
than tumor (cases 2, 6, 16).
By considering a threshold as for qMSP, a sample was
defined as “methylated” if it had an average methylation
across 51 CpGs higher than 20%. Using this threshold,
13/20 (65%) tumors and 12/20 (60%) normal samples
were methylated. Among the 3 normal samples with
higher degree of methylation than the neoplastic coun-
terpart, case 2 showed the largest difference of average
methylation level between PET and normal.
Pyrosequencing results overlapped those obtained by
qMSP in both PET and normal pancreas when the sta-
tus of the 10 CpGs included in the qMSP assay (from
CpG3 to CpG12; see Figure 3) was considered; in fact,
the average methylation level of these 10 CpGs by
Figure 1 Schematic representation of the RASSF1 locus on
chromosome 3p21.3 and its transcription map. White boxes
represent the exons and the bold line represents the introns.
RASSF1A, RASSF1B and RASSF1C variants are generated by differential
promoter usage (arrows). RASSF1D, E, F, G are variants derived from
alternative splicings of RASSF1A. Two CpG islands (black bands
below the sequence) are associated to RASSF1 promoter region:
CpG island A (737 bp, 85 CpGs) extending in the promoter region
of RASSF1A, D, E, F and G; CpG island C (1365 bp, 139 CpGs) in the
regulatory region of RASSF1B and C.
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pyrosequencing vs the level of methylation by qMSP
showed a good correlation (r = 0.78, P = 0.0001).
RASSF1A is methylated in normal pancreas
Regardless of technique used, our data indicate that
RASSF1A methylation occurs in normal pancreas, as pre-
viously reported by others [2,4,5,30], and presents inter-
individual variability in terms of frequency and level.
RASSF1A mRNA expression in PET is lower than that of
matched normal pancreas and inversely correlates with
methylation level of CpG island A
Expression of RASSF1A mRNA was assessed in 13 PETs
and matched normal pancreas by qRT-PCR. Expression
was lower in PET than in normal in 11 of 13 cases,
equal to an average difference of 6.8 fold (P = 0.003)
(Figure 4A and Additional file 2, Table S2).
Figure 2 Analysis of DNA methylation by pyrosequencing. Representative results of pyrosequencing showing analysis of 9 CpGs in the first
exon of RASSF1A (from CpG6 to CpG14). The y-axis represents the signal intensity of luminescence in relative luminescence units (RLU) emitted
following nucleotide base incorporation into the sequence, while the x-axis shows the nucleotide dispensation order, indicated by the letters
below each graph: E, enzyme mix; S, substrate; A, G, C, T, nucleotides. The sequence in the upper left of the boxes is the region subjected to
pyrosequencing analysis, where the nine letters Y indicate the respective cytosine in the 9 CpG sites (from CpG6 to CpG14) whose methylation
status is shown here. Values in light blue boxes are the percentages of methylation of each CpG. Percentages of methylation represent the ratio
between signal intensities of C and T in each C of a CpG site. Dispensations corresponding to the potentially methylated cytosine (C or T after
bisulfite treatment) are highlighted in grey. Each panel depicts a representative sample showing no methylation (panel A, sample N1), partial
methylation (panel B, sample T8) and high methylation (panel C, sample N2) levels.
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Figure 3 Methylation status of CpG island A in PET, normal pancreas and cell lines. Panel A shows the methylation level of the 51 CpGs
analyzed by pyrosequencing in the 20 matched normal/tumor samples. Numbers on the left refer to normal (N) and tumor (T) samples of the
20 PET listed in Table 1. Each of the 51 CpGs, 17 in the promoter region and 34 in the first exon, is represented by a square. Numbers on top
show the location of CpG dinucleotides and transcription start site is indicated (+1). Any CpG is represented by a square that has one of four
grey levels according to the proportion of methylation detected, namely white, light grey, dark grey and black indicating a level of methylation
of 0-20%, 20-40%, 40-60% and > 60%, respectively. Black lines on top of squares indicate location of qMSP and MSP assays spanning CpGs 3 to
12 and CpGs 21 to 34, respectively. Panel B reports the methylation status of the 51 CpGs in the three indicated PET cell lines (CM, QGP1 and
BON), where C and D indicates untreated control cells and cell lines treated with demethylating agent, respectively.
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The comparison between mRNA expression levels and
methylation status by MSP showed that the two events
were not significantly associated (Wilcoxon test, P=
0.07). When comparing RASSF1A expression data with
percent of methylation by qMSP, Spearman’s test
revealed the presence of an inverse correlation (r=-0.35,
P = 0.08), which became significant when the average
methylation of the 51 CpGs of pyrosequencing data was
considered (r=-0.57, P = 0.01) (Figure 5A). A major con-
tribution to this latter association was provided by the
first exon (r=-0.61, P = 0.007) while methylation of pro-
moter did not correlate significantly (r=-0.44, P > 0.05)
(Figure 5B).
We then searched for a role of specific CpGs in the
transcription regulation of RASSF1A using pyrosequen-
cing data (Additional file 3, Figure S2). The highest
degree of correlation was found for CpG5 (inner graph
in Additional file 3, Figure S2). The expression of
RASSF1A inversely correlated with the methylation of
this CpG (r=-0.78, P = 0.001).
RASSF1A expression is present in PET cell lines despite a
strong methylation in CpG island A and is enhanced by
treatment with demethylating agents
The three PET cell lines CM, QGP1, BON showed a
level of methylation above 90% by qMSP (Additional file
3, Figure S1B). Pyrosequencing analysis confirmed the
high level of methylation throughout the CpG island A
(Figure 3B). Interestingly, RASSF1A was always
expressed at similar level in all the untreated cell lines
(Figure 4B). RASSF1A was always expressed in all the
untreated cell lines, but at higher level in BON com-
pared to QGP1 and CM.
In order to evaluate the effect of methylation on gene
expression of RASSF1A, the three cell lines CM, QGP1
and BON were treated with the demethylating agent 5’-
aza-2’-deoxycytidine (DAC). Treatment reduced methy-
lation by about 25% from the starting level. The main
changes of methylation regarded the CpGs included in
the first exon (Figure 3B). However, DAC treatment
induced a significant increase of RASSF1A expression in
QGP1 and CM, but not in BON cell line (Figure 4B).
The mRNA expression levels and the average methyla-
tion of the 51 CpGs within CpG island A showed a sig-
nificant inverse correlation (r=-0.73, P = 0.004).
Isoform RASSF1C is highly expressed in PET at variance
with the other six isoforms generated from RASSF1 locus
Seven mRNA isoforms could potentially be expressed by
the RASSF1 locus and four of them (RASSF1-A, D, E
and F) are generated from differential splicing of
RASSF1A (Figure 1).
PCR products of RASSF1 isoforms A, D, E and F are
resolved by microfluidic chip electrophoresis (Figure 6).
RASSF1A was detected in all PETs while the splicing
variants D, E and F were rarely seen: RASSF1F was
found in one PET (T7) and two normal pancreas (N3,
Table 2 Pyrosequencing analysis of 20 matched samples:
average methylation values of 51 CpGs in CpG island A
of RASSF1A, of which 17 CpGs in the promoter and 34
CpGs in the first exon
Average methylation (%)
Cases*
Promoter First Exon CpG island A
N1 4 2 3
T1 2 4 3
N2 34 75 60
T2 20 11 14
N3 29 14 19
T3 37 19 25
N4 2 2 2
T4 23 8 13
N5 37 22 28
T5 59 56 57
N6 27 18 22
T6 29 10 17
N7 40 35 37
T7 53 52 52
N8 47 37 40
T8 77 46 57
N9 43 32 35
T9 46 29 35
N10 35 34 34
T10 49 72 64
N11 37 38 38
T11 38 43 41
N12 28 18 22
T12 42 66 57
N13 25 34 31
T13 67 65 66
N14 4 3 4
T14 49 30 37
N15 36 28 31
T15 50 37 41
N16 14 8 10
T16 10 9 9
N17 3 2 2
T17 3 5 4
N18 4 18 13
T18 32 7 16
N19 10 6 8
T19 25 37 33
N20 25 36 32
T20 43 80 67
*N = normal pancreas, T = PET.
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N5), RASSF1D/RASSF1E was expressed in only one
sample (N5).
Of the remaining three isoforms, RASSF1G was always
absent in PET and normal pancreas, while variant B was
always expressed in both normal and PET with no sig-
nificant difference (data not shown). Conversely,
RASSF1C expression level in PETs was significantly
higher than that found in normals in 11 of 13 cases (P
= 0.001) (Figure 4C), having a fold average expression
ratio PET/normal of 11.4.
CpG island C is never methylated
Pyrosequencing analysis revealed that none of the 37
CpGs of CpG island C is methylated in PETs and nor-
mal pancreas.
Lower expression of RASSF1A and higher expression of
RASSF1C in PET with respect to normal pancreas are
concomitant events
We tested the relationship between RASSF1A and
RASSF1C analyzing the expression ratio PET/normal.
Comparison of RASSF1A PET/normal and RASSF1C PET/
normal expression ratios suggested that the lower expres-
sion of the first and the higher expression of the second
are two events occurring concomitantly (r = 0.7, P = 0.01).
CpG island C is never methylated in PET cell lines and
treatment with demethylating agents enhances mRNA
expression of RASSF1C
No methylation was detected in 37 CpGs of CpG island
C in PET cell lines using pyrosequencing and RASSF1C
Figure 4 Expression of RASSF1A and RASSF1C in PET, normal pancreas and PET cell lines. The expression levels of RASSF1A (A) and of
RASSF1C (C) in 13 PET (black bars) and matched normal pancreas (white bars) are shown. Expression data are the mean of three measures
obtained by quantitative RT-PCR. Data were normalized using the expression level of the gene RPLPO as an internal reference. Data were
analyzed according to the comparative method and standard (= 1) was represented by the average expression of all samples. Numbers under
the bars refer to PET cases listed in Table 1. Expression level of RASSF1A (B) and of RASSF1C (D) (mean ± SD) in PET cell lines QGP1, BON, CM are
represented by white bars for control untreated (CTRL) and dark grey bars for 5’-aza-2’-deoxycytidine (DAC) treated cells. In (A) and (C) an
asterisk indicates a significant difference of expression of RASSF1A and RASSF1C in normal with respect to PET (t-test, P < 0.05) (see Additional file
2, Table S2 for expression data and statistics). In (B) and (D) an asterisk indicates a significant difference of expression in treated cells with respect
to the same cells untreated (t-test, P < 0.05).
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transcript was always found at similar level in untreated
cells (Figure 4D). However, treatment of cell lines with
DAC upregulated RASSF1C expression significantly in
QGP1 and CM, but not in BON cell line.
Discussion
The suggestion that RASSF1A silencing by methylation
is involved in the pathogenesis of PET has been sup-
ported by the presence of methylation in the CpG island
A of the gene [1-5]. However, all studies used the same
qualitative method to assess methylation and RASSF1A
expression has never been analyzed in PET.
In this study we conducted an exhaustive analysis of
RASSF1 methylation status in order to define its puta-
tive role as a possible tumor specific and transcription
regulatory event occurring in PET.
We first analyzed RASSF1 methylation by the qualita-
tive MSP assay because this was the method used in
previous studies on PET, and found methylation in 80%
of cases, a frequency similar to that reported in those
studies [1-5]. However, MSP is highly sensitive recogniz-
ing as little as 0.1% of methylated alleles [31], thus clas-
sifying a sample as methylated on the basis of a minimal
proportion of methylated target. We then performed
qMSP that has been previously used for the evaluation
Figure 5 Relationship between the expression of RASSF1A and
methylation of CpG island A. (A) Expression of RASSF1A in
function of the average methylation of 51 CpGs in the CpG island A
in 13 PET (black diamond) and matched normal pancreas (white
diamond). A linear regression through the data (y = -0.0673x +
2.0228, R2 = 0.337) describes the relationship between methylation
and gene expression. Only tumor samples had an average
methylation > 40% while all normal tissues had an average
methylation < 40%. (B) RASSF1A gene expression vs average
methylation of 17 CpGs in the promoter (graph on the left) and vs
that of 34 CpGs in the first exon (graph on the right) in PET cases
(black diamond) and normal pancreas (white diamond). A linear
regression through the data describes the relationship between
methylation of promoter (y = -0.0452x + 1.2697, R2 = 0.1314) and
first exon (y = -0.0572x + 1.5418, R2 = 0.3569) and gene expression.
Figure 6 Identification of RASSF1A and its splicing variants by
PCR. Electropherograms of PCR products obtained by amplification
of cDNA. PCR products were loaded on microfluidic DNA 1000 chip
and run on a 2100 Bioanalyzer instrument (Agilent Technologies).
The amplicon of isoform A is 229 bp, both isoforms D and E
generate a 241 bp peak, due to the insertion of 12 bp to the
sequence of isoform A, and therefore cannot be separated, while
the amplicon of isoform F is the shortest one (118 bp). Peaks at
15bp and 1500 bp are the lower and upper size markers,
respectively. Case T9 expresses isoform A, N5 expresses isoform A
and D/E, T7 expresses isoform A and F.
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of methylation status of RASSF1A in tumors other than
pancreatic [6-8,10]. This assay analyzes a region of CpG
island A that has never been investigated in PET. By
this quantitative assay, all PET showed some degree of
methylation but only 55% of cases had at least 20% of
their alleles methylated.
In normal pancreas, RASSF1 methylation was found in
65% of cases by MSP, a value that fit within the range
of published studies that used the same technique
[2,4,5]. By qMSP assay, 45% of normals had at least 20%
of their alleles methylated.
Finally, we obtained a detailed mapping of RASSF1A
methylation by pyrosequencing, assessing the level of
methylation of each of 51 CpGs within CpG island A,
also encompassing those explored by MSP and qMSP
approaches. Pyrosequencing provided a portrait of the
complexity of the methylation pattern of tumor cells,
where RASSF1A methylation showed a high variability
in terms of distribution and level within and among
samples. Similar to pancreas, a very complex distribu-
tion of methylation of RASSF1A was found in breast
cancer [19].
Our pyrosequencing data showed that most of normal
and tumor samples had an average methylation levels of
the CpG island A below 40%, with the exception of one
normal (case 2) and seven tumors, having values above
40% (Table 2). To classify samples as “methylated”, we
applied the same cut-off used for qMSP (an average
methylation level higher than 20%). Methylated samples
were 13/20 (65%) in PET and 12/20 (60%) in normal
pancreas. In matched samples, the average methylation
level of the CpG island A was higher in PET than in
normal samples in 15/20 (75%) cases (P = 0.01). Among
the 3 normal samples with higher degree of methylation
than the neoplastic counterpart, case 2 showed the lar-
gest difference of average methylation level between
PET and normal. We repeated the pyrosequencing ana-
lysis of this case with same results and did not find any
particular features in the clinical profile of the patient to
associate to the abnormal methylation data.
Although the overall CpG island A methylation level
revealed by pyrosequencing was higher in PET than in
normal tissue (Figure 3), normal pancreas displayed con-
siderable methylation levels. The common occurrence of
methylation of RASSF1A in normal pancreas suggests
that this epigenetic event might represent a “field
defect”, consisting in widespread epigenetic changes
arising early in the pancreas before tumor onset, a
hypothesis previously suggested [32,33].
When comparing the three techniques employed in
this study to investigate the methylation status, MSP
showed different results from those obtained by both
qMSP and pyrosequencing. This is consistent with the
qualitative (MSP) and quantitative (qMSP and
pyrosequencing) nature of these approaches. Conversely,
qMSP and pyrosequencing gave comparable results (cor-
relation r = 0.78), thus supporting the choice of using
the same cut-off for both quantitative results to classify
a sample as methylated.
Whatever the method used to detect methylation, the
majority of cases showed concordantly methylated or
unmethylated tumor/normal pairs, and, when discor-
dant, the methylation was higher in tumor in most
cases, except case 2 (Table 2). This raises the question
of whether methylation affects the expression of RASSF1
gene. Indeed, none of the previous papers suggesting
the inactivation of RASSF1A in PET due to hypermethy-
lation analyzed gene expression [2,4,5]. In the present
work, we evaluated the mRNA expression of RASSF1
variants and showed that: i) all PETs and their matched
normal tissues expressed RASSF1A; ii) the average
expression of RASSF1A in PET was 6.8 times lower than
that in normal tissues (see Figure 4A and Additional file
2, Table S2); iii) the overall extent of RASSF1A methyla-
tion in PET correlated inversely with its expression and
the role of methylation of the first exon seems more
important than that of the promoter region (see Figure
5). Accordingly, a correlation between RASSF1A expres-
sion and the average methylation of the 51 CpGs of
island A was found in two of the three PET cell lines
analyzed. In all untreated cell lines RASSF1A was always
expressed despite a strong methylation in CpG island A;
in particular, BON cell line showed a higher level of
RASSF1A expression compared to QGP1 and CM.
Moreover, the treatment with the demethylating agent
5’-aza-2’-deoxycytidine enhanced significantly RASSF1A
expression in QGP1 and CM, but not in BON. This dif-
ference in expression levels and response to demethylat-
ing treatment is consistent with a possibly different
genetic background. Indeed, it has been recently shown
that CM, QGP1, and BON harboured different gene
mutations; in particular, they had mutations in FLT1/
VEGFR1, FGFR3, and PIK3CA, respectively [34].
The expression of RASSF1A splicing isoforms D, E, F
and G, and that of the major variants deriving from
alternative promoter usage, RASSF1B and RASSF1C,
has never been studied in PET. Here we report that
RASSF1 isoforms D, E, F were rarely expressed in PET
and normal pancreas; RASSF1G was never found;
RASSF1B was always expressed in both PET and nor-
mal pancreas, with no significant difference; RASSF1C
expression was averagely 11.4 times higher in PET
than in normal tissue. Pyrosequencing analysis revealed
that all the CpGs within CpG island C lacked methyla-
tion in both tumor and normal tissues. The same
situation was found in PET cell lines, where CpG
island C was never methylated, and RASSF1C was
always expressed. Interestingly, treatment with 5’-aza-
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2’-deoxycytidine enhanced mRNA expression signifi-
cantly in two of the three cell lines.
The finding of hyperexpression of RASSF1C in PET is
of great interest in the light of the recently reported role
of RASSF1C in inhibiting ß-catenin degradation [35].
Thus, RASSF1C overexpression may represent a pathoge-
netic event in PET contributing in sustaining Wnt signal-
ing that has been recently shown to regulate proliferation
of pancreatic ß-cells [36]. Moreover, RASSF1C has also
been implicated in promoting cell migration and attenu-
ating apoptosis in breast cancer cells [37].
Conclusions
RASSF1A gene is frequently methylated in PET and at
higher level than in normal pancreas. However, as no
more than 75% of cases show RASSF1A to be more
methylated in PET than normal pancreas, RASSF1 gene
methylation cannot be considered a marker lesion for
this neoplasm.
RASSF1A is always expressed in PET and normal pan-
creas and its levels are inversely correlated with gene
methylation status.
Isoform RASSF1C is highly expressed in PET at var-
iance with the other six isoforms generated from
RASSF1 locus; this suggesting that RASSF1C might play
a pathogenetic role in tumor development, in the light
of the recent demonstration of its involvement in the
regulation of Wnt pathway.
Additional material
Additional file 1: Additional methods. The file completes the
description of methods and experimental conditions employed to obtain
the data. The description is subdivided in: quantitative methylation-
specific PCR (qMSP), PCR conditions used to amplify samples for DNA
pyrosequencing, quantitative reverse-transcription polymerase chain
reaction (qRT-PCR) and immunofluorescence procedure.
Additional file 2: Additional tables. Table S1. Oligonucleotides and
experimental conditions used for quantitative MSP (qMSP), DNA
pyrosequencing, microfluidic chip-electrophoretic separation (RT-PCR)
and quantitative RT-PCR (qRT-PCR). The table lists the primers sequences
and the PCR conditions used in qMSP, RT-PCR and qRT-PCR. Table S2.
Expression and statistics data of RASSF1A and RASSF1C in PET and normal
pancreas obtained by quantitative RT-PCR (qRT-PCR). The table provides
the expression data of RASSF1A and RASSF1C and the statistical analysis.
Additional file 3: Additional figures. Figure S1. Analysis of
methylation of RASSF1A by methylation-specific PCR (MSP) and
quantitative MSP (qMSP). The figure shows examples of MSP results and
a graph representing data obtained by qMSP. Figure S2. Pearson’s
correlations (r) between expression of RASSF1A and the average
methylation of single CpGs. The graph shows the Pearson’s correlation
values (r) between RASSF1A expression level and the average methylation
level for each CpG of the CpG island A.
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